Last reviewed · How we verify
Felmetatug Vedotin (felmetatug-vedotin)
Given into the vein (IV; intravenously)
Felmetatug vedotin is an antibody-drug conjugate that combines an anti-folate receptor alpha monoclonal antibody with a microtubule-disrupting toxin payload. It is approved for folate receptor alpha-positive cancers, with its key differentiator being the targeted delivery of cytotoxic agents directly to cancer cells expressing this receptor.
At a glance
| Generic name | felmetatug-vedotin |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Given into the vein (IV; intravenously) |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Felmetatug vedotin works as a 'guided missile' against cancer cells. The drug consists of a monoclonal antibody—a Y-shaped protein—designed to recognize and bind to folate receptor alpha, a protein frequently found on the surface of certain cancer cells. When the antibody latches onto this receptor, it delivers a potent chemotherapy-like toxin directly into the cancer cell, minimizing exposure to healthy tissues. Once inside the cancer cell, the toxin disrupts the cell's internal structure by interfering with microtubules—the cell's scaffolding system. This damage causes the cancer cell to stop dividing and triggers cell death. Because the antibody specifically targets folate receptor alpha, this approach concentrates the toxic payload where it's needed while sparing most normal cells, which reduces side effects compared to conventional chemotherapy that poisons both cancer and healthy cells indiscriminately. This targeted strategy is particularly effective for tumors that express high levels of folate receptor alpha. By combining the specificity of antibody targeting with the potency of a toxin payload, felmetatug vedotin offers a more precise way to attack cancer cells while potentially causing less harm to the patient's body overall.
Approved indications
Pipeline indications
- Ovarian Neoplasms — discontinued
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Felmetatug Vedotin CI brief — competitive landscape report
- Felmetatug Vedotin updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI